The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection
Open accessAbstract
Connexins are widely distributed proteins in the body that are crucially important for heart and brain function. Six connexin subunits form a connexon or hemichannel in the plasma membrane. Interactions between two hemichannels in a head-to-head arrangement result in the formation of a gap junction channel. Gap junctions are necessary to coordinate cell function by passing electrical current flow between heart and nerve cells or by allowing exchange of chemical signals and energy substrates. Apart from its localisation at the sarcolemma of cardiomyocytes and brain cells, connexins are also found in mitochondria where they are involved in the regulation of mitochondrial matrix ion fluxes and respiration. Connexin expression is affected by age and gender as well as several pathophysiological alterations such as hypertension, hypertrophy, diabetes, hypercholesterolemia, ischemia, post-myocardial infarction remodelling or heart failure, and post-translationally connexins are modified by phosphorylation/de-phosphorylation and nitros(yl)ation which can modulate channel activity. Using knockout/knockin technology as well as pharmacological approaches, one of the connexins, namely connexin 43, has been identified to be important for cardiac and brain ischemia/reperfusion injury as well as protection from it. Therefore, the current review will focus on the importance of connexin 43 for irreversible injury of heart and brain tissue following ischemia/reperfusion and will highlight the importance of connexin 43 as an emerging therapeutic target in cardio- and neuroprotection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Musil, L. S., & Goodenough, D. A. (1991) · The Journal of cell biology · doi:10.1083/jcb.115.5.1357 · Cited by 767
Cerebral preconditioning and ischaemic tolerance
Gidday, J. M. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1927 · Cited by 751 · cited 2×
“Myocardial ischemia/reperfusion injury and cardioprotection) but also exerts protective effects in the brain (Gidday, 2006).”
BackgroundLi, J., Patel, V. V., Kostetskii, I., Xiong, Y., Chu, A. F., Jacobson, J. T., Yu, C., Morley, G. E., Molkentin, J. D., & Radice, G. L. (2005) · Circulation Research · doi:10.1161/01.res.0000181132.11393.18 · Cited by 223 · cited 2×
“Loss of N-cadherin reduces Cx43 expression at gap junctions (Li et al., 2008;Li et al., 2005;Palatinus et al., 2011;Zhu et al., 2010).”
BackgroundDanesh-Meyer, H. V., Kerr, N. M., Zhang, J., Eady, E. K., O'Carroll, S. J., Nicholson, L. F. B., Johnson, C. S., & Green, C. R. (2012) · Brain · doi:10.1093/brain/awr338 · Cited by 179
Cited by
Heusch, G., & Gersh, B. J. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw224 · Cited by 676
Liang, Z., Wang, X., Hao, Y., Qiu, L., Lou, Y., Zhang, Y., Ma, D., & Feng, J. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00703 · Cited by 84
Metadata
- Authors
- Schulz, R., Görge, P. M., Görbe, A., Ferdinandy, P., Lampe, P. D., & Leybaert, L.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 153
- Pages
- 90-106
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W642235081
- Cited by
- 223
- References
- 4
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection. https://app.cochat.ai/papers/10.1016/j.pharmthera.2015.06.005
- The paper
- Schulz, R., Görge, P. M., Görbe, A., Ferdinandy, P., Lampe, P. D., & Leybaert, L. (2015). Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2015.06.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.